Prolonged Ventricular Depolarization and Sudden Death in the Community

描述（由申请人提供）： 摘要：美国心脏性猝死（SCD）的年发病率在20万至30万之间，绝大多数是由于致命性心律失常。在该领域已经出现了一种共识，即划定多个预测因子，这些预测因子可以组合为风险评分，以增强SCD风险分层。在562例植入ICD的患者中，我们以前曾报道过心室复极延长，表现为12导联ECG上QRS间期的持续时间增加（？QRSd）是复发性室性心律失常的预测因子，与其他人报告的结果一致。现在我们在普通人群中进行的一项单独研究的初步结果表明？QRSd可以在没有严重LVSD的情况下观察到，并且在更广泛的社区中是SCD的潜在预测因子。本申请的目的是评价QRSd作为一般人群SCD风险预测因子的潜力。俄勒冈州意外猝死研究是一项在俄勒冈州波特兰市区进行的基于人群的病例对照研究。1，000，000）。使用1100例SCD病例和1100例匹配对照的临床信息和DNA样本，我们建议检验这一假设，即延长的心室去极化独立地有助于CAD室性心律失常基质，并且该基质受到中等风险表型性状（如2型糖尿病）以及个体基因组特征的调节。将在1200例SCD病例的单独人群中验证识别出的候选基因变体。我们的具体目标是：1.确定QRSd对SCD风险的独立贡献。2.确定表型决定因素？QRSd及其对SCD风险的贡献。3.评价冠心病患者心室除极影响基因变异在SCD易感性中的作用。一项已建立和正在进行的基于人群的病例对照研究以及临床电生理学、流行病学和基因组学方面的专业知识的现成可用性将有助于对QRSd如何增强SCD风险预测进行详细评价。考虑到12导联ECG的广泛适用性和相对较低的成本，该提案对SCD风险分层的任何增强都可能具有显著的临床意义。

DESCRIPTION (provided by applicant): ABSTRACT The annual incidence of sudden cardiac death (SCD) in the US ranges between 200,000 - 300,000 and the vast majority occur due to fatal arrhythmia. A consensus has emerged in the field for delineation of multiple predictors that could be combined as a risk score to enhance SCD risk stratification. In a population of 562 patients implanted with ICDs, we have previously reported that prolonged ventricular repolarization measured as increased duration of the QRS interval on the 12-lead ECG (?QRSd) was a predictor of recurrent ventricular arrhythmias, consistent with findings reported by others. Now our preliminary findings from a separate study in the general population indicate that ?QRSd can be observed in the absence of severe LVSD and is a potential predictor of SCD in the broader community. The goal of this application is to evaluate the potential of QRSd as a predictor of SCD risk in the general population. The Oregon Sudden Unexpected Death Study is an ongoing population-based case-control study in the Portland, Oregon metro area (pop. approx. 1,000,000). Using clinical information and DNA samples from 1100 SCD cases and 1100 matched controls, we propose to test the hypothesis that prolonged ventricular depolarization independently contributes to the ventricular arrhythmia substrate in CAD and that this substrate is modulated by intermediate risk phenotypic traits such as type 2 diabetes as well as the individual's genomic profile. Candidate gene variants identified will be validated in a separate population of 1200 SCD cases. Our specific aims are: 1. To determine the independent contribution of QRSd toward risk of SCD. 2. To identify phenotypic determinants of ?QRSd and their contribution to SCD risk. 3. To evaluate the role of ventricular depolarization-affecting gene variants in susceptibility to SCD among patients with CAD. An established and ongoing population-based case-control study and the ready availability of expertise in clinical electrophysiology, epidemiology and genomics will facilitate this detailed evaluation of how QRSd may enhance SCD risk prediction. Given the wide applicability and relatively low cost of the 12-lead ECG, any enhancement of risk stratification of SCD by this proposal is likely to have significant clinical relevance.